title: Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
abstract: Data comparing real-world effectiveness of the glucagon-like peptide-1 receptor agonists (GLP-1RAs) exenatide once weekly (QW) and liraglutide in the treatment of type 2 diabetes (T2D) are limited. Furthermore, there is limited information on exenatide QW or liraglutide response by glycemic control and insulin use status. This study identifies 1-year glycosylated hemoglobin (HbA1c) and weight outcomes with exenatide QW and liraglutide in the real-world setting overall and in insulin-naive patients with uncontrolled T2D.
  
  
  
  This retrospective cohort study using national electronic medical record data compared 1-year HbA1cand weight outcomes in patients with T2D prescribed exenatide QW or liraglutide. Included patients were adults (≥18 years old) with T2D who were GLP-1RA naive when newly prescribed exenatide QW or liraglutide between January 1, 2012, and March 31, 2013 (index date). Outcomes were reported descriptively overall and in subsets of insulin-naive patients with baseline HbA1c≥7.0% or ≥9.0%. Multivariable linear regression analyses were performed to estimate adjusted change in HbA1cand weight.
  
  
  
  The study included 808 exenatide QW and 4333 liraglutide patients. Mean (SD) age was 57 (11) years in both groups. Mean baseline HbA1cwas 8.3% (1.5%) in exenatide QW patients and 8.4% (1.6%) in liraglutide patients (P = 0.66); 16 (2%) of the exenatide QW and 1099 (25.4%) of the liraglutide patients were newly prescribed insulin on the index date (P < 0.001). Adjusted mean HbA1cchange at 1 year was -0.37% (95% CI, -0.53% to -0.21%) for exenatide QW and -0.37% (95% CI, -0.55% to -0.18%) for liraglutide. Adjusted HbA1creduction was more pronounced in insulin-naive patients with baseline HbA1c≥7.0% (-0.71% and -0.80% for the exenatide QW and liraglutide patients, respectively, P > 0.05) and ≥9.0% (-1.73% and -1.57% for exenatide QW and liraglutide patients, respectively, P > 0.05). Mean (adjusted) weight loss was -2.22 kg (95% CI, -3.06 to -1.37 kg) with exenatide QW and -2.21 kg (95% CI, -3.18 to -1.23 kg) with liraglutide.
  
  
  
  Exenatide QW and liraglutide lead to similar HbA1cand weight reductions at 1 year in the real-world setting. Greater HbA1creductions occurred in insulin-naive patients with baseline HbA1c≥7.0%. Both agents are appropriate options for patients needing antidiabetes therapy to lower HbA1cwhile promoting weight loss.
authors.affiliation: Department of Pharmacotherapy & Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, Utah. Electronic address: carrie.mcadam-marx@pharm.utah.edu.
authors.forename: Carrie
authors.initials: C
authors.lastname: McAdam-Marx
authors.affiliation: AstraZeneca, Fort Washington, Pennsylvania.
authors.forename: Hiep
authors.initials: H
authors.lastname: Nguyen
authors.affiliation: Department of Pharmacotherapy & Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, Utah.
authors.forename: Marisa B
authors.initials: MB
authors.lastname: Schauerhamer
authors.affiliation: Department of Pharmacotherapy & Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, Utah.
authors.forename: Mukul
authors.initials: M
authors.lastname: Singhal
authors.affiliation: Department of Pharmacotherapy & Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, Utah.
authors.forename: Sudhir
authors.initials: S
authors.lastname: Unni
authors.affiliation: Department of Pharmacotherapy & Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, Utah.
authors.forename: Xiangyang
authors.initials: X
authors.lastname: Ye
authors.affiliation: AstraZeneca, Fort Washington, Pennsylvania.
authors.forename: David
authors.initials: D
authors.lastname: Cobden
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis*; D001835:Body Weight / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D000077270:Exenatide; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D000069450:Liraglutide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use; D012189:Retrospective Studies; D014688:Venoms / Q000627:therapeutic use; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D001786:Blood Glucose; D000077270:Exenatide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000069450:Liraglutide; D010455:Peptides; D014688:Venoms; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
keywords: diabetes mellitus; exenatide; glycemic control; liraglutide; observational study; weight